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Abstract: Background: Over the past decade, three new drugs have been approved for the treatment
of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze
whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods:
The study was conducted retrospectively, analyzing the medical records of 105 patients with genetic
diagnoses of familial amyloidotic polyneuropathy followed at the two referral centers for the disease
in Sicily, Italy. Of these, 71 received disease-modifying therapy, while 34 received only symptomatic
treatment or no therapy. Results: The most used treatment in our patient cohort was tafamidis,
followed by liver transplantation, patisiran, inotersen, and diflunisal. The median survival was
significantly longer for treated vs. untreated patients (12 years vs. 8 years). In the 71 patients who
received disease-modifying treatment, the presence of cardiac involvement, weight loss, or autonomic
dysfunction at diagnosis was not related to survival. Conversely, patients diagnosed in the early
stage of the disease (PND 1) had significantly longer survival than those diagnosed in the late stage
(PND 2–4).
Keywords: hereditary transthyretin amyloidosis; ATTRv; non-V30M; polyneuropathy; survival;
tafamidis; patisiran; inotersen
1. Introduction
Hereditary amyloid transthyretin (ATTRv) amyloidosis with polyneuropathy is a sys-
temic adult-onset disease that affects the sensorimotor and autonomic functions along with
other organs (especially the heart, gastrointestinal tract, eyes, and kidneys) [1]. The disease
has an autosomal dominant pattern of inheritance and is considered a worldwide disease
with an estimated global prevalence of 38,000 persons [2–5]. Patients with the most frequent
neuropathic mutation, V30M (p.V50M), have characteristically early onset (<50 years) in
endemic areas, whereas late onset (>50 years) is prevalent in non-endemic areas. Other
variants, such as T49A (p.T69A) and E89Q (p.E109Q), often present with an early onset
even in non-endemic areas [6–10]. The most common hereditary cardiac transthyretin
amyloidosis is that associated with V122I (p.V142I), carried by 3.9% of individuals of
African descent [11].
TTR is a transport protein in the serum and cerebrospinal fluid that carries the thyroid
hormone thyroxine and retinol-binding protein bound to retinol. It is encoded by the TTR
gene located in the 18th chromosome. The protein is a 55kDa homotetramer synthesized in
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the liver, choroid plexus, and retinal pigment epithelium for secretion into the bloodstream,
cerebrospinal fluid, and eye, respectively. Each monomer is a 127-residue polypeptide rich
in beta sheet structure [12–14]. The presence of missense mutations in altering the amino
acid sequence can make the tetramer less stable, favoring its dissociation. The misfolded
monomers aggregate, generating amyloid fibrils, which precipitate into tissues [15,16]. In
peripheral nerves, fibrils cause axon and Schwann cell damage, resulting in the predomi-
nant loss of small-fiber axons characteristic of early-onset cases, while vasculopathy can
also determine the pathogenesis of neuropathy in late-onset cases [17]. Once polyneuropa-
thy begins, it progresses rapidly, evolving in three defined stages: in the first, patients have
a sensory polyneuropathy that leads to difficulty walking without assistance; in the second,
assistance with walking is required; and in the last stage, patients are wheelchair-bound or
bedridden. Death occurs on average 12 years after the onset of the disease in the absence of
therapy, but survival can vary with different mutations [18]. The presence of amyloidotic
heart disease can influence this classical progression, and the survival for variants with
prevalent cardiological involvement is generally shorter [19,20]. The clinical phenotype
based on the mutations is not always predictable, as there is considerable variability in
clinical expression even within the same family [21].
In the last three decades, there has been an overall improvement in the management of
this disease, and various disease-modifying therapies have been developed [15,16]. More-
over, awareness of being ahead of a multisystem pathology requiring a multidisciplinary
approach has also improved the management of symptoms [18,22]. In parallel, increased
diagnostic tools and awareness of the disease have reduced the diagnostic delay, favoring
an earlier start of treatment [4,23].
To date, some studies on the efficacy of new drugs in modifying the outcomes of
patients over short periods have been performed, but information on survival is lacking,
mainly in non-V30M patients [24–32]. A recent paper showed that in non-endemic late-
onset ATTRv amyloidosis, long-term treatment with tafamidis is safe and efficacious, and
the severity of polyneuropathy at the start of treatment is the main predictor for disease
progression on tafamidis [30].
The aim of this work was to analyze whether current therapies have prolonged sur-
vival in Sicilian patients affected by ATTRv amyloidosis, representing an almost exclusively
non-V30M patient population. Another purpose was to update the clinical–epidemiological
data in Sicily [10], where diagnosed cases have increased dramatically in the last five years.
2. Materials and Methods
We conducted a retrospective study, including all patients and carriers who had a
pathogenic missense mutation on the TTR gene followed in the two Sicilian referral centers
for the disease (Amyloidosis Centre of Messina University Hospital and Amyloidosis
Centre of Palermo University Hospital) from January 1991 until December 2020. The study
was approved by the Ethical Committee of Messina Province. All methods were performed
in accordance with the relevant guidelines and regulations. The diagnosis was based on
clinical and neurophysiological features and confirmed by positive genetic testing for TTR
gene variants. In some patients, usually the probands, especially in the first half of the
observed period, the diagnosis was also corroborated by biopsy, in most cases of the sural
nerve. We also performed TTR gene analysis in asymptomatic relatives close to the typical
age of onset, with the aim of following them serially to reduce the diagnostic delay and,
consequently, to start therapy in a timely manner.
The clinical data collected from available medical records consisted of:
• The age at onset, diagnosis, and death, or age of living patients as of 31 December
2020,
• The family history of neuropathy or ATTR amyloidosis,
• The type of TTR mutation,
• The clinical and neurological examination at diagnosis,
• Electromyography and nerve conduction studies at diagnosis,
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• The presence of autonomic nervous system involvement at diagnosis, when available
and based on autonomic cardiovascular tests, or, in their absence, based on clinical
evaluation,
• The presence of cardiac involvement at diagnosis based on ECG, echocardiogram,
atrial natriuretic hormone dosage (nt-pro-BNP), and, in some cases, 99 m Tc-3, 3-
diphosphono-1, 2-propanodicarboxylic acid scintigraphy or cardiac magnetic reso-
nance (CMR) with T2-weighted imaging and late gadolinium enhancement,
• Sural nerve biopsy in selected cases,
• Therapeutic drugs (or procedures) and the overall duration of their administration,
• Symptomatic treatment.
Statistical Analysis
The characteristics of the patients were described by using standard descriptive
statistics. All the results are documented as mean values, ranges, or percentages when
appropriate. To assess the relationships between treatment and survival, between clinical
characteristics in treated patients at the onset and survival, and between mutation (E89Q vs.
F64L) and survival, curves were estimated by Kaplan–Meier analysis and compared using
the log rank test. The effect size is expressed as the hazard ratio, and statistical uncertainty
is expressed as 95% confidence intervals. The comparison of the age of onset and disease




This study examined 159 patients with pathogenic mutations in the TTR gene at the
two reference centers from 1991 to 2020, 135 in Messina and 24 in Palermo. The most
frequently encountered mutation was F64L (p.F84L) in 81 patients, followed by E89Q in
56, V122I (p.V142I) in 11, T49A in 8, and V30M in 3. Among them, 40 subjects (20 men
and 20 women, mean age 46.6, range 28–66) were still asymptomatic as of 31 December
2020. In addition, 14 patients (4 men and 10 women, mean age 58.3 years, range 41–78)
were affected by carpal tunnel syndrome, without other symptoms or signs of ATTRv
amyloidosis. The clinical characteristics of the other 105 patients with ATTRv amyloidosis
are described in Table 1. Of the 105 patients, 71 received disease-modifying therapy and
34 did not receive specific drugs for the disease.
Table 1. Clinical characteristics. All time intervals are expressed in years.
Total F64L E89Q V122I T49A V30M
Patients, n (m/f) 105 (68/37) 51 (36/15) 38 (21/17) 6 (6/0) 8 (3/5) 2 (2/0)
Age at onset, mean (range) 59.3 (33.0–81.2) 66.6 (46.3–81.2) 51.7 (36.4–76.2) 65.3 (62.3–69.1) 43.6 (33.0–56.3) 62.4 (53.7–71.1)
Age at diagnosis, mean (range) 62.2 (33.9–85.3) 70.1 (52.3–85.3) 53.5 (40.2–74.8) 70.1 (66.0–76.1) 45.4 (33.9–57.7) 65.9 (56.4–75.3)
Diagnostic delay (years), mean (range) 2.8 (0–16) 3.5 (0–16) 1.9 (0–6) 4.8 (3–7) 1.75 (0–4) 3.5 (3–4)
Probands, n (%) 50 (47.6) 35 (68.6) 7 (18.4) 1 (16.7) 1 (12.5) 0
Late onset, n (%) 81 (77.1) 50 (98.0) 22 (57.8) 6 (100) 1 (12.5) 2 (100)
Neurologic symptoms at diagnosis, n (%) 103 (98.0) 51 (100) 36 (94.7) 6 (100) 8 (100) 2 (100)
Sensory 97 (92.4) 45 (88.2) 36 (94.7) 6 (100) 8 (100) 2 (100)
Motor 60 (57.1) 37 (72.5) 15 (39.5) 0 6 (75) 2 (100)
Gait difficulties 46 (43.8) 32 (62.7) 11 (28.9) 0 1 (12.5) 2 (100)
CTS 62 (59.0) 30 (58.8) 24 (63.2) 4 (66.7) 3 (37.5) 1 (50)
Cardiac involvement at diagnosis, n (%) 48 (45.7) 9 (17.6) 31 (81.6) 5 (83.3) 3 (37.5) 0
Dysautonomia at diagnosis, n (%) 60 (57.1) 24 (47.1) 26 (68.4) 1 (16.7) 8 (100) 1 (50)
CADT score point loss 5.5 6.2 5.1 6 5.2 2
Weight loss, n (%) 53 (50.5) 25 (49.0) 16 (42.1) 1 (50) 5 (87.5) 2 (100)
Living patients, n (%) 59 (56.1) 27 (52.9) 23 (60.5) 3 (50) 4 (50) 2 (100)
Disease duration in living pt. (yrs) 6.15 (0.4–16) 4.8 (0.4–16) 6.8 (0.5–13.6) 8.9 (4.9–13.6) 7.3 (5.5–8.6) 9.6 (5.5–13.7)
Deceased patients, n (%) 46 (43.8) 24 (47.0) 15 (39.4) 2 (33.3) 5 (62.5) 0
Disease duration in deceased pt. (yrs) 8.4 (3.1–13.0) 8.5 (4.0–11.8) 8.2 (3.1–13.0) 7.5 (6.3–8.7) 9.2 (7.0–12.9) N.A.
Late onset: >50 years. Sensory: abnormal pinprick or vibration or joint position sense at neurological examination. Motor: Medical Research
Council scale ≤4 due to polyneuropathy in two or more muscles. Gait recorded as abnormal due to polyneuropathy at neurological
examination. Cardiac involvement at diagnosis: presence of cardiac amyloidosis demonstrated by echocardiography, scintigraphy, or
cardiac resonance. Dysautonomia at diagnosis: presence of postural hypotension, gastrointestinal, or genito-urinary dysfunction due to
autonomic failure based on clinical judgment. Weight loss: number of patients with unexplained body weight reduction ≥5 kg since onset
of symptoms. CTS, carpal tunnel syndrome; CADT, Compound Autonomic Dysfunction Test [33]; N.A., not applicable.
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Three mutations usually have late onset (F64L, V122I, and V30M), T49A has early
onset, and the age of onset of patients with the E89Q variant is usually around 50. Clinical
evaluations at diagnosis show frequent cardiac involvement in E89Q and V122I patients,
while dysautonomia is frequently present in T49A patients. New diagnoses progressively
increased in the 30-year period, reaching 45 cases in the last five years (Figure 1). The most
frequently identified variant over the past five years was F64L, in 29 of 45 patients.
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Figure 1. Number of diagnoses for five-year periods.
Regarding the type of polyneuropathy, in the 105 patients who developed polyneu-
ropathy, a nerve conduction study at diagnosis showed an axonal pattern in 94, demyeli-
nating in 5, and mixed in 6. Sural nerve biopsy was performed in 16 patients, among which
10 were positive to Congo Red staining; in all of these cases there was a marked loss of
myelinated fibers.
3.2. Actual Scenario
As of 31 December 2020, 73 living patients and 40 asymptomatic carriers underwent
regular follow-up, and 44 patients received disease-modifying treatment: 23 patisiran
(3 also received liver trans lants), 17 tafamidis, and 4 inotersen. Only one patient was liver-
transplanted and did not receive other therapies. No other disease-modifyi g treatments
are currently in use in Sicily. In light of these results, the current prevalence of ATTRv
amyloidosis in Sicily is 15.0/1,000,000 (12.1/1,000,000 excluding patients with carpal tunnel
syndrome only).
3.3. Comparison of Treated and Untreated Patients
Table 2 shows the characteristics of patients who received a disease-modifying treat-
ment, compared to those patients who did not.
The two groups did not show a significant difference in age of onset (p = 0.24) and
were quite similar, considering patient TTR mutations and symptoms at diagnosis. The
type of treatment administered was measured as years of therapy received, and in the case
of patients who underwent liver transplantation (six in this cohort), the years of therapy
were considered as all years of life after the transplant. The Kaplan–Meyer curves of
survival in the two groups are represented in Figure 2. The survival was longer for treated
patients (p = 0.0004).
The median survival of treated and untreated patients was 12 years vs. 8 years, and
the hazard ratio for untreated/treated was 2.55. Furthermore, considering only deceased
patients, the disease duration was longer for treated patients than untreated patients
(p = 0.04) (Table 2).
Brain Sci. 2021, 11, 545 5 of 11
Table 2. Comparison of treated vs. untreated patients and details of treatments received.
Treated Untreated p
Patients, n (m/f) 71 (51/20) 34 (16/18)
Age at onset, mean (range) 58.5 (33.0–81.2) 61.0 (37.5–75.7) 0.24
Diagnosis before 2011, n (%) 17 (43) 23 (57)
Diagnosis after 2011, n (%) 54 (83) 11 (17)





Neurologic symptoms at diagnosis, n (%) 69 (97) 34 (100)
Cardiac involvement at diagnosis, n (%) 37 (52) 11 (32)
Dysautonomia at diagnosis, n (%) 43 (60) 17 (50)
Weight loss at diagnosis, n (%) 39 (55) 14 (41)
Years of disease, total (mean) 531 (7.48) 220 (6.47)
Years of treatment received (n patients/mean) 299 (71/4.2)
Tafamidis 192 (52/3.7)




Diagnostic delay, total (mean) 180 (2.5) 119 (3.5)
Time out of treatment for other reasons 52 101
Deceased patients, n (%) 24 (34) 22 (65)
Disease duration in deceased patients, mean (range) 9.1 (4–13) 7.7 (3–12) 0.04
Significant p-values are in bold.
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3.4. Relation between Clinical Characteristics at the Onset and Survival in Treated Patients
In the 71 treated patients, survival was not significantly different as it related to the
presence of cardiac involvement (p = 0.79), weight loss (p = 0.1), or autonomic dysfunction
(p = 0.05) at diagnosis. Furthermore, survival was not significantly different comparing
patients with E89Q vs. those with F64L mutation (p = 0.19). A very significant difference
(p = 0.0002) was found between patients who had a polyneuropathy disability score
(PND) [34] of 1 (sensory disturbance but preserved walking capability) at diagnosis vs.
patients with a more advanced polyneuropathy score (Figure 3).
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3.5. Symptomatic Drugs
In 51 of the 105 patients with polyneuropathy, a specific tr a ment fo neuropathic pain
had been admin ster d. However, thes fi re likely to have b en underreported in
th clinical notes, especially in the first half of the p riod under review, because the general
practitioner sometimes managed these drugs. The most used drugs for neuropathic pain
were pregabalin (38 cases), gabapentin (4), amitriptyline (21), duloxetine (12), and tramadol
(6). The most used symptomatic treatments for autonomic symptoms were fludrocortisone,
midodrine, loperamide, and octreotide. Cardiac dysfunction was generally treated with
diuretics, ace inhibitors, beta blockers, and implantable cardioverter defibrillators. No
patients underwent a heart transplant.
4. Discussion
4.1. Epidemiological Aspect
We reported long-term data on a cohort of patients with genetically confirmed ATTRv
amyloidosis followed at the two referral centers for amyloidosis in Sicily, the University
Hospitals of Messina and Palermo, between January 1991 and July 2020.
In the last five years, the increased attention to this disease has led to a significant
increase in diagnoses, now almost double those in the previous five years [10]. These
findings, together with the lengthening of disease duration, also show a significant increase
in prevalence compared to the 2015 data (15 vs. 8.8 per million), the highest in Italy and
one of the highest in Europe among non-endemic areas [4,5].
Patients diagnosed in the last five years were mainly carriers of the F64L mutation.
This variant has been evidently underdiagnosed, given the advanced age at onset, the
almost exclusively neuropathic phenotype, and the high frequency of apparently sporadic
cases [9]. Furthermore, two new mutations were detected in the Sicilian cohort: the well-
known V30M with the typical neuropathic phenotype, described in non-endemic areas, and
the V122I mutation (in six patients), commonly described as causing an almost exclusive
cardiac phenotype [35] that, in our experience, instead determined in all cases a neuropathic
phenotype, with cardiac amyloidosis in five of them [21,36].
4.2. Diagnostic Delay and Carpal Tunnel Syndrome
The diagnostic delay has been significantly reduced in recent years [4]. For this
reason, in the group of untreated patients mainly in the period before 2011 (23 of 34), the
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diagnostic delay was significantly higher (3.5 vs. 2.5 years). Conversely, most of the treated
patients were diagnosed after 2011 (54 of 71), the year the European Medical Agency
(EMA) approved the first drug for ATTRv amyloidosis, tafamidis meglumine, which led to
increased medical awareness [24,25,29].
Among the 113 subjects carrying pathogenic mutations who underwent regular follow-
up, 40 were asymptomatic carriers, 59 had polyneuropathy and/or involvement of other
organs, and 14 had only carpal tunnel syndrome. Although there was no indication to start
treatment in the latter group, recent studies have shown that in most biopsies obtained
from the transverse carpal ligament of such patients, amyloid is present [37,38]. In our
opinion, the possibility that therapy with TTR stabilizers or TTR mRNA silencers could
delay the onset of systemic amyloidosis in such patients should be evaluated. While
waiting for further clarification on this topic, we will perform frequent clinical exams (three
times a year), neurophysiological studies (NCS and cardiovascular autonomic testing,
one to two times a year), and imaging studies (cardiac MRI and/or serial scanning with
99 m Tc-3, 3-diphosphono-1, 2-propanodicarboxylic acid once a year) to promptly start
treatment [39–41].
4.3. Treatment Used
The percentage of patients receiving treatment has increased considerably, owing to
the availability of tafamidis, approved by the EMA in November 2011 for adult patients
with transthyretin-related polyneuropathy. This drug acts as a pharmacologic chaperone
that stabilizes the properly folded tetramer of TTR protein by binding in one of the two
thyroxine-binding sites [42]. The U.S. Food and Drug Administration (FDA) in 2019 and
the EMA in 2020 approved tafamidis also for the treatment of transthyretin-mediated
cardiomyopathy (ATT-CM) [43]. Although it is not always able to alter the disease, it is
certainly very well tolerated and manageable [29].
Almost exclusively non-Met30 patients composed our cohort, therefore in some cases
we preferred to shift patients to the new oligonucleotide drugs that have been shown to
be unmistakably effective even in this population. Overall, both drugs, and particularly
patisiran, have demonstrated better efficacy compared to tafamidis [27,28,44–46]. Despite
this, in 17 of 44 patients, tafamidis was still used based on the abovementioned advantages.
The long-term survival after liver transplantation is encouraging in patients with
early-onset V30M, but the efficacy is controversial in non-Met30 patients, especially when
associated with lower body mass index or older age, which was probably the reason
why only six patients underwent liver transplantation in our cohort [34,47–49]. Different
studies have explained why many patients continue to worsen after liver transplant.
Tissue accumulation of TTR can continue, likely because TTR amyloid fibers promote
subsequent deposition of wild-type TTR [50]. The ability of amyloid seeding to promote
fibrillogenesis could be particularly relevant in patients with cardiac amyloid deposits.
In recent years, to inhibit this process, peptides designed to complement the structures
of TTR fibrils inhibiting TTR fibril seeding have been tested. However, these molecules
have not been verified in clinical phase studies [15,51,52]. Patients with a cardiac or mixed
(cardio/neuro) phenotype, as often happens in ATTRE89Q amyloidosis, who have cardiac
amyloid deposits at the time of diagnosis, would require combined heart–liver transplant
to avoid the seeding effect. However, the exclusion of older patients and those with
severe systemic disease, limited organ availability, and the risks associated with surgery
and life-long immunosuppression represent difficulties that often discourage clinicians
from proposing combined transplantation [53]. In our experience, in some cases patients
rejected the transplant option because a close relative who underwent transplantation had
a negative outcome. Finally, in patients with ATTRF64L amyloidosis, the indications for
transplantation are very limited due to the advanced age at diagnosis. It is therefore not
surprising that the most commonly used therapy in Sicily in the period under observation
was tafamidis (despite its only being available since 2011) rather than liver transplantation.
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Patisiran and inotersen will probably be the most commonly used drugs in the coming
years, awaiting further pharmacologic developments.
4.4. Effect on Survival
The survival analysis performed in this study was an expression of the effects of
different treatments, which in some cases were used at different times in the same patient
and in others even simultaneously (for example, in the three transplant patients currently
taking patisiran). Obviously, this limitation of the study made it possible to formulate an
overall judgment only on the progress achieved in ATTRv amyloidosis.
Overall, the major role in prolongation in terms of the survival of treated patients
was mainly played by tafamidis, which was the treatment used most widely and for the
longest period in this cohort by the number of years (192 years of treatment, 3.7 years per
patient). In descending order, the other therapies were liver transplant (52 years, 8.7 years
per patient), patisiran (34 years, 1.9 years per patient), inotersen (14 years, 2 years per
patient), and diflunisal (only 4 years altogether, 2 years per patient) (Table 2).
The survival curves between treated and untreated patients show a clear difference
8–9 years after the onset of symptoms. Disease duration in deceased patients was also
significantly different. This difference could become even greater in the coming years
thanks to the new treatments.
In this study, there was no prognostic difference in the patients treated in relation to the
presence of cardiac involvement, autonomic dysfunction, or malnutrition at diagnosis [30].
This unexpected finding could be, in part, because mutations with a higher prevalence of
cardiac and autonomic involvement at diagnosis may cause disease onset at a younger age,
and consequently in patients with much longer life expectancy. As expected, when survival
is related to the PND score at diagnosis, patients in stage 1 have a higher rate of survival.
The patients in the study cohort were diagnosed in almost all cases in a neurological clinic;
therefore, the presence of neurological symptoms at onset was constant in almost all cases.
Consequently, the presence of polyneuropathy at diagnosis does not discriminate between
variants or depend on the age at onset.
5. Conclusions
As predicted in previous reports [9,10], the prevalence of transthyretin amyloidosis is
increasing significantly in Sicily owing to greater attention being paid to this pathology.
Disease-modifying therapies, in percentage mainly represented by tafamidis at present,
have significantly improved the survival of patients. When patients are diagnosed with a
PND score of 1, their overall survival is longer.
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